SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
1-Year Return
0.41%
This Quarter Return
+2.74%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$611M
AUM Growth
-$2.34M
(-0.38%)
Cap. Flow
-$42.9M
Cap. Flow
% of AUM
-7.02%
Top 10 Holdings %
Top 10 Hldgs %
32.55%
Holding
133
New
19
Increased
28
Reduced
40
Closed
21
Top Buys
| 1 |
Teva Pharmaceuticals
TEVA
|
$24.2M |
| 2 |
Nova
NVMI
|
$10.8M |
| 3 |
Viking Therapeutics
VKTX
|
$8.42M |
| 4 |
Check Point Software Technologies
CHKP
|
$7.75M |
| 5 |
Biohaven
BHVN
|
$6.66M |
Top Sells
| 1 |
Broadcom
AVGO
|
$30.5M |
| 2 |
Kezar Life Sciences
KZR
|
$14.3M |
| 3 |
Salesforce
CRM
|
$8.64M |
| 4 |
Cytokinetics
CYTK
|
$8.44M |
| 5 |
Praxis Precision Medicines
PRAX
|
$7.54M |
Sector Composition
| 1 | Healthcare | 71.97% |
| 2 | Technology | 19.72% |
| 3 | Consumer Discretionary | 3.62% |
| 4 | Communication Services | 3.05% |
| 5 | Utilities | 0.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SHLT
76
DELISTED
SHL Telemedicine Ltd American Depositary Shares
SHLT
| $2.13M | 0.34% |
632,456
| – | – |
|
77
Dyne Therapeutics
DYN
$1.88B
| $2.03M | 0.32% |
+56,504
| New | +$2.03M |
|
78
Viridian Therapeutics
VRDN
$1.52B
| $1.96M | 0.31% |
+86,094
| New | +$1.96M |
|
79
Nutrien
NTR
$27.7B
| $1.96M | 0.31% |
40,730
| – | – |
|
80
Alnylam Pharmaceuticals
ALNY
$59.4B
| $1.93M | 0.31% |
+7,000
| New | +$1.93M |
|
|
CMMB
81
Chemomab Therapeutics
CMMB
$15.8M
| $1.91M | 0.3% |
+303,644
| New | +$1.91M |
|
82
Perion Network
PERI
$411M
| $1.85M | 0.29% |
234,609
| – | – |
|
83
Workday
WDAY
$61.7B
| $1.83M | 0.29% |
+7,500
| New | +$1.83M |
|
|
84
Kezar Life Sciences
KZR
$28M
| $1.59M | 0.25% |
20,517
-184,651
| -90% | -$14.3M |
|
85
Analog Devices
ADI
$121B
| $1.53M | 0.24% |
6,660
-6,340
| -49% | -$1.46M |
|
86
Astria Therapeutics
ATXS
$395M
| $1.5M | 0.24% |
136,582
-26,260
| -16% | -$289K |
|
87
Scholar Rock
SRRK
$3.12B
| $1.34M | 0.21% |
+166,866
| New | +$1.34M |
|
|
ALMS
88
Alumis Inc. Common Stock
ALMS
$475M
| $1.34M | 0.21% |
125,000
| – | – |
|
89
Werewolf Therapeutics
HOWL
$61.7M
| $1.33M | 0.21% |
626,810
| – | – |
|
90
Qualcomm
QCOM
$172B
| $1.33M | 0.21% |
7,800
-11,025
| -59% | -$1.87M |
|
91
Oric Pharmaceuticals
ORIC
$1.05B
| $1.32M | 0.21% |
+128,396
| New | +$1.32M |
|
92
Kyverna Therapeutics
KYTX
$157M
| $1.22M | 0.19% |
248,651
+12,622
| +5% | +$61.7K |
|
93
Capricor Therapeutics
CAPR
$272M
| $938K | 0.15% |
+61,698
| New | +$938K |
|
|
CLYM
94
Climb Bio, Inc. Common Stock
CLYM
$158M
| $926K | 0.15% |
181,970
-33,209
| -15% | -$169K |
|
95
Aprea Therapeutics
APRE
$8.74M
| $743K | 0.12% |
270,000
| – | – |
|
96
Vir Biotechnology
VIR
$714M
| $699K | 0.11% |
93,329
-68,722
| -42% | -$515K |
|
|
ELEV
97
DELISTED
Elevation Oncology
ELEV
| $648K | 0.1% |
1,079,762
+749,762
| +227% | +$450K |
|
98
ADC Therapeutics
ADCT
$382M
| $646K | 0.1% |
205,036
-480,511
| -70% | -$1.51M |
|
99
Monte Rosa Therapeutics
GLUE
$303M
| $626K | 0.1% |
118,103
-256,897
| -69% | -$1.36M |
|
100
4D Molecular Therapeutics
FDMT
$309M
| $526K | 0.08% |
48,702
-193,824
| -80% | -$2.1M |
|